Trauma (Emergency, Injury, Surgery) | Phase II Developments

Revance Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection

Lead Product(s): Daxibotulinumtoxin A

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The company has announced a decision to complete enrollment in its JUNIPER Phase 2 trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury.

Leading BioSciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint

Lead Product(s): LB1148

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

Data demonstrate efficacy on an approvable endpoint that may also result in substantial cost savings based on reductions ICU and hospital length of stay.

Inotrem

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock

Lead Product(s): Nangibotide

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Roche Diagnostics GmbH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 21, 2020

Details:

Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

PhaseBio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

Lead Product(s): PB2452

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: SFJ Pharmaceuticals

Deal Size: $120.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 10, 2020

Details:

The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.

Galecto

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Galecto to merge with onetime Celgene partner PharmAkea

Lead Product(s): PAT-1251

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PAT-1251

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Pharmakea therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 07, 2020

Details:

The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.

Find

Find Drugs for Trauma (Emergency, Injury, Surgery) in Phase II Clinical Development

Phase II

Product Type

Companies

Revance Therapeutics

Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection

Leading BioSciences

Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint

Inotrem

Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock

PhaseBio Pharmaceuticals

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

Galecto

Galecto to merge with onetime Celgene partner PharmAkea